Neuberger Berman Group
DNLI icon

Neuberger Berman Group’s Denali Therapeutics DNLI Stock Holding History

Neuberger Berman Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
+9,742
New +$200K ﹤0.01% 2091
2024
Q1 		– Sell
-288,922
Closed -$6.2M – 1856
2023
Q4 		$6.2M Buy
+288,922
New +$5.72M ﹤0.01% 1018
2019
Q3 		– Sell
-10,000
Closed -$208K – 1548
2019
Q2 		$208K Sell
10,000
-20,000
-67% -$448K ﹤0.01% 1494
2019
Q1 		$696K Buy
+30,000
New +$628K ﹤0.01% 1195

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's DNLI Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 9,742 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #2091 among its holdings. This is a return to the name: Neuberger Berman Group previously reported a position in DNLI as recently as Q4 2023.

Neuberger Berman Group first reported a position in DNLI in Q1 2019 and has held it in 4 quarters since. The position peaked at $6.2M in Q4 2023. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Neuberger Berman Group held 9,742 shares of Denali Therapeutics worth $251K as of Q2 2026.
  • Denali Therapeutics was a new Neuberger Berman Group position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2091 holding.
  • Neuberger Berman Group first reported a position in Denali Therapeutics in Q1 2019 and has held it in 4 quarters since.
  • Neuberger Berman Group's Denali Therapeutics position peaked at $6.2M in Q4 2023.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.